Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net Revenues	$ 333,018	$ 317,896	$ 253,667
Cost of Sales	144,662	116,748	97,419
Gross Profit	188,356	201,148	156,248
Operating Expenses:
Research and development	24,335	23,911	23,729
Selling and marketing	31,273	26,780	26,486
General and administrative	57,148	49,541	44,345
Product recall costs (adjustment)	(350)	5,596	0
Acquisition and transaction related costs	6,940	392	3,890
Litigation and select legal costs	13,510	2,803	2,080
Restructuring costs	1,109	0	687
Change in fair value of acquisition consideration and settlement	0	(909)	(6,293)
Total Operating Expenses	133,965	108,114	94,924
Operating Income	54,391	93,034	61,324
Other Income (Expense):
Interest income	17	0	142
Interest expense	(1,189)	(1,878)	(2,632)
RADx grant income	0	1,000	0
Other, net	1,098	(1,705)	459
Total Other Expense, Net	(74)	(2,583)	(2,031)
Earnings Before Income Taxes	54,317	90,451	59,293
Income Tax Provision	11,858	19,044	13,107
Net Earnings	$ 42,459	$ 71,407	$ 46,186
Earnings Per Share Data:
Basic earnings per common share	$ 0.97	$ 1.65	$ 1.08
Diluted earnings per common share	$ 0.96	$ 1.62	$ 1.07
Common shares used for basic earnings per common share	43,583	43,259	42,855
Effect of dilutive stock options and restricted share units	792	753	319
Common shares used for diluted earnings per common share	44,375	44,012	43,174
Anti-Dilutive Securities:
Common share options and restricted share units	154	203	893